Home > Archive > 2006 >

Volume 25, Number 1 (March)

Exenatide (pages 6-18)

Candis M. Morello, Pharm.D., C.D.E., and Steven V. Edelman, M.D.

Exenatide (Byetta) is the first in a new class of drugs called incretin mimetics. It offers people with Type 2 diabetes an opportunity to improve their glycemic control, restore first- and second-phase insulin secretion, and lose weight. This article reviews the mechanism of action, efficacy, safety, and dosing.
Drug treatmentIncretin mimetics

Standards of Medical Care – 2006 (Part 1) (pages 20-31)

American Diabetes Association

The latest edition of the American Diabetes Association’s Standards of Care contains some significant revisions. Several major sections have been added and some others have been extensively modified. The Editor has underscored the importance of these changes with comments throughout this first installment.
Professional guidelines

Cardiac Autonomic Neuropathy (pages 34-38)

Raimund I. Herzog, M.D., Deborah Chyun, Ph.D., R.N., F.A.H.A., and Lawrence H. Young, M.D.

Cardiac autonomic neuropathy has recently been recognized as an additional risk factor for cardiac morbidity and mortality in diabetes. Providers will increasingly encounter this entity as the epidemic of diabetes progresses. In this article, the authors detail the risks for an various forms of autonomic dysfunction, their clinical manifestations, and available treatments.
Complications and comorbiditiesCardiovascular disease
Complications and comorbiditiesNeuropathy

Learning to Use Pramlintide (pages 42-46)

Diane M. Karl, M.D.

Pramlintide (Symlin), an analog of the hormone amylin, was recently approved for use by people with Type 1 or Type 2 diabetes who use insulin. Among its effects are improved postprandial glycemia, reduced HbA1c, and weight loss. Dr. Karl clearly and simply reviews the mechanism of action, efficacy, and administration of pramlintide.
Drug treatmentPramlintide

Symlin and Byetta – Two New Antihyperglycemic Medications (pages 49-52)

Davida Kruger, M.S.N., A.P.R.N.-B.C., B.C.-A.D.M.

2005 saw the introduction of two new exciting drugs that offer improved diabetes care for millions who have diabetes. The author looks at both of these exciting, first-in-class medications, comparing indications, safety profile, and recommendations for optimal use.
Drug treatmentIncretin mimetics
Drug treatmentPramlintide

New Additions to Our Tool Chest (pages 54-55)

Daniel L. Lorber, M.D.

Exciting new medications deserve comment. The Editor explains the biological principles behind exenatide and pramlintide and how devotion to basic science research was responsible for the development of these exciting therapeutic advances.
Drug treatmentIncretin mimetics
Drug treatmentPramlintide